| REVIEW ARTICLE |
|
| Ahead of Print |
|
|
Glucocorticoid-free treatment of systemic lupus erythematosus: Is it feasible?
Syahrul Sazliyana Shaharir1, Caroline Gordon2, John A Reynolds2
1 Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre, Rheumatology Unit, Kuala Lumpur, Malaysia
2 Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital; Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK
Correspondence Address:
Syahrul Sazliyana Shaharir,
Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre, Rheumatology Unit, Cheras, Kuala Lumpur 56000
Malaysia
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/injr.injr_97_22
|
|
|
Glucocorticoids (GCs) remain the mainstay of treatment in systemic lupus erythematosus (SLE) more than 60 years after their discovery. Despite their effectiveness in controlling disease activity, the long-term use of GC often causes side effects that increase morbidity and mortality in SLE patients. Evidence from randomized controlled trials on the appropriate dosing and tapering of GC in SLE is scarce. Historically, high doses of GC were used in the treatment of SLE. Fortunately, there are emerging data showing a lower dose of GC is equally effective compared to a higher GC in controlling disease activity and has fewer adverse effects. The introduction of various GC-sparing immunosuppressive (IS) treatments such as cyclophosphamide (CYC), azathioprine, mycophenolate mofetil, calcineurin inhibitors, and biologic agents has assisted in reducing the GC doses in SLE. The aims of this narrative review are to give an overview on the GC mechanisms of actions, the strategies to reduce GC-related toxicity, the evidence of low GC dose protocols and finally to discuss the viability of GC-free treatment of SLE.
|
|
|
|
|
|
|
Search Pubmed for